Appln. No. Amdt. Dated: November 25, 2003 Attorney Docket No.: MSU 4.1-674

### AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

### LISTING OF CLAIMS

5

Claims 1 - 14 (Cancelled)

## -15-(Original)

A method for inhibiting a pathogenic trematode in a warm-blooded animal or human infected with the pathogenic trematode comprising:

- (a) providing a composition containing inhibitory amount of at least one anthraquinone selected 1,2,8-trihydroxy-3-methyl from the group consisting of 1,2,8-trihydroxy-3anthraquinone (compound 3) and anthraquinone (compound 6) hydroxymethyl pharmaceutically acceptable carrier; and
- (b) and administering the composition to the warmblooded animal or human to inhibit the pathogenic trematode.

### -16-(Original)

The method of Claim 15 wherein the anthraquinone is inhibitory at a dosage of 1 to 1,000 micrograms per milliliter or gram.

Appln. No. Amdt. Dated: November 25, 2003 Attorney Docket No.: MSU 4.1-674

# -17-(Original)

The method of Claim 15 wherein the anthraquinone is administered to the warm-blooded animal or human orally, subcutaneously, intraperitoneally, intravenously, topically, intranasally, or rectally.

5

10

5

### -18-(Original)

A method for inhibiting a pathogenic trematode in a warm-blooded animal or human infected with the pathogenic trematode comprising:

- (a) providing а composition containing an 1,2,8-trihydroxy-3-methyl-0- $\beta$ -Dinhibitory amount of glucopyranoside anthraquinone (compound 7) and at least one anthraquinone selected from the group consisting of 1,8dihydroxy $-2-O-\beta-D-g$ lucopyranoside anthraquinone (compound 4) 1,8-dihydroxy-2-0-malonyl-(1-6)- $\beta$ -D-glucopyranoside anthraquinone (compound 5) in a pharmaceutically acceptable carrier; and
- (b) and administering the composition to the warmblooded animal or human to inhibit the pathogenic trematode.

### -19-(Original)

The method of Claim 18 wherein the composition further includes an inhibitory amount of at least one anthraquinone selected from the group consisting of 1,2,8-trihydroxy-3-methyl anthraquinone (compound 3) and 1,2,8-trihydroxy-3-hydroxymethyl anthraquinone (compound 6).

### -20-(Original)

The method of Claim 18 wherein the anthraquinone is inhibitory at a dosage of 1 to 1,000 micrograms per milliliter or gram.

#### -21-(Original)

The method of Claim 18 wherein the anthraquinone is administered to the warm-blooded animal or human orally, subcutaneously, intraperitoneally, intravenously, topically, intranasally, or rectally.

Appln. No. Amdt. Dated: November 25, 2003 Attorney Docket No.: MSU 4.1-674

Claims 22 - 33 (Cancelled)